Premium
Role of endothelin‐1 in the hyper‐responsiveness to nitrovasodilators following acute NOS inhibition
Author(s) -
Bourque Stephane L,
Whittingham Heather A,
Brien Susan E,
Davidge Sandra T,
Adams Michael A
Publication year - 2012
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.2011.01696.x
Subject(s) - sodium nitroprusside , medicine , endothelin receptor , vasoconstriction , nifedipine , constriction , blood pressure , pharmacology , antagonist , mean arterial pressure , endothelin 1 , endocrinology , vasodilation , receptor antagonist , nitric oxide , receptor , heart rate , calcium
BACKGROUND AND PURPOSE Acute NOS inhibition in humans and animals is associated with hypersensitivity to NO donors. The mechanisms underlying this phenomenon have not been fully elucidated. The purpose of the present study was to assess whether hypersensitivity to NOS‐blockade is linked to endothelin‐1 (ET‐1) signalling. EXPERIMENTAL APPROACH Sprague Dawley rats were instrumented with indwelling arterial and venous catheters for continuous assessments of haemodynamic parameters and drug delivery, respectively. Mesenteric arteries were isolated and tested for reactivity by wire myography. KEY RESULTS NOS blockade with L‐N G ‐nitroarginine methyl ester (L‐NAME) caused a pronounced increase in arterial blood pressure (BP) (∼40 mmHg). In L‐NAME‐treated animals, the dose of sodium nitroprusside (SNP) required to cause a significant reduction in arterial BP was lower than in vehicle‐treated rats ( P < 0.001), and the magnitude of the reduction in BP was greater. Similar results were obtained with other NO mimetics, but not isoprenaline; moreover, decreasing the BP back to baseline levels with prazosin after L‐NAME treatment did not attenuate the hyper‐responsiveness to NO donors. The increased responsiveness to NO donors was abolished by pretreatment with the ET A/B receptor antagonist, PD145065, or the ET A receptor‐specific antagonist ABT627. Ex vivo , L‐NAME treatment potentiated the constriction induced by big endothelin‐1 (bET‐1), the precursor to active ET‐1, but had no effect on the ET‐1‐mediated constriction. CONCLUSIONS AND IMPLICATIONS These data suggest that the increased sensitivity to NO donors is mediated, at least in part, by ET‐1 in vivo , and the mechanism may involve the conversion of bET‐1 to ET‐1.